A phase II study of PAD therapy (bortezomib, doxorubicin, and dexamethasone) for relapsed or refractory multiple myeloma.
Not Applicable
- Conditions
- relapse or refractory multiple myeloma
- Registration Number
- JPRN-UMIN000004514
- Lead Sponsor
- Department of Hematology and Respiratory Medicine, Kochi University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who have a serious active infection 2. Patients who have complication of active double cancer 3. Women who are or may be pregnant or are nursing 4. Patients with grade 2 or severer peripheral neuropathy or peripheral neurogenic pain (CTCAE v4.0) 5. Patient diagnosed with interstitial pneumonia in high resolution CT, and judged to improper to administer bortezomib 6. Other patients who are unfit for enrollment in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method